Industry
Biotechnology
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Loading...
Open
1.03
Mkt cap
77M
Volume
314K
High
1.05
P/E Ratio
-2.27
52-wk high
2.12
Low
0.99
Div yield
N/A
52-wk low
0.92
Portfolio Pulse from
December 19, 2024 | 12:30 pm
Portfolio Pulse from
December 12, 2024 | 4:00 pm
Portfolio Pulse from
November 15, 2024 | 6:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 11:15 am
Portfolio Pulse from Benzinga Newsdesk
October 14, 2024 | 4:09 pm
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 9:30 am
Portfolio Pulse from Vandana Singh
October 09, 2024 | 2:22 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.